4D-150 IVT

Phase 2

MOLECULAR PARTNERS AG (MOLN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

MOLNPhase 2$161M

4D-150 IVT Phase 2 Est. Readout

4D-150 IVT• Neovascular (Wet) Age-Related Macular Degeneration215

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Neovascular (Wet) Age-Related Macular Degeneration

View Full Landscape

Drug Information

Target Indication

Neovascular (Wet) Age-Related Macular Degeneration

Clinical Trial

NCT05197270

Last updated: 8/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MOLN

MOLECULAR PARTNERS AG

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

4D-150 IVT (3E10 vg/eye)Phase 3

Macular Neovascularization Secondary to Age-Related Macular Degeneration

MP0420Phase 3

COVID-19

4D-150 IVT (3x10^10 vg)Phase 3

Diabetic Macular Edema (DME)

MP0250 plus BOR+DEXPhase 2

Multiple Myeloma in Relapse

[212Pb]Pb-MP0712Phase 2

Large Cell Neuroendocrine Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts